GWOXI
國璽幹細胞應用技術股份有限公司
GWOXI is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is GXCPC1 (Phase 3 trial authorized in principle, Osteoarthritis), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| GXCPC1 | — | Phase 3 trial authorized in principle | Osteoarthritis | Taiwan | 2025-05-12 | Company disclosure |
| GXNPC1 | — | Phase 3 trial authorized in principle | Chronic stroke | Taiwan | 2026-08-13 | Company disclosure |
| GXIPC1 | — | — | — | — | 2025-10-21 | Company disclosure |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.